Enterprise Value

143.6M

Cash

111.8M

Avg Qtr Burn

-12.55M

Short % of Float

0.21%

Insider Ownership

0.00%

Institutional Own.

1.29%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Elafibranor Details
Primary biliary cholangitis, Liver disease

PDUFA

Approval decision

VS-01 Details
Acute-on-Chronic liver failure, Liver disease

Phase 2

Data readout

Nitazoxanide (NTZ) Details
Non-alcoholic steatohepatitis , Acute-on-Chronic liver failure, Liver disease

Phase 2

Initiation

GNS561 Details
Liver disease, Cholangiocarcinoma

Phase 1b

Data readout

Elafibranor Details
Non-alcoholic steatohepatitis

Failed

Discontinued